These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

458 related articles for article (PubMed ID: 37124542)

  • 21. Integrated single-cell and bulk RNA sequencing analyses reveal a prognostic signature of cancer-associated fibroblasts in head and neck squamous cell carcinoma.
    Yang Y; Ma B; Han L; Xu W; Du X; Wei W; Liao T; Ji Q; Qu N; Wang Y
    Front Genet; 2022; 13():1028469. PubMed ID: 36568368
    [No Abstract]   [Full Text] [Related]  

  • 22. Disulfidptosis characterizes the tumor microenvironment and predicts immunotherapy sensitivity and prognosis in bladder cancer.
    Pan G; Xie H; Xia Y
    Heliyon; 2024 Feb; 10(3):e25573. PubMed ID: 38356551
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Integrated analysis of single-cell and bulk RNA-sequencing identifies a signature based on T-cell marker genes to predict prognosis and immunotherapy response in bladder cancer.
    Shi X; Dong A; Yang Y; Zheng G; Wang N; Yang C; Wang Y; Lu J; Jia X
    J Cancer Res Clin Oncol; 2023 Sep; 149(12):9733-9746. PubMed ID: 37244876
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Single-cell and bulk RNA sequencing reveal cancer-associated fibroblast heterogeneity and a prognostic signature in prostate cancer.
    Liu W; Wang M; Wang M; Liu M
    Medicine (Baltimore); 2023 Aug; 102(32):e34611. PubMed ID: 37565899
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of a basement membrane-related genes signature with immune correlation in bladder urothelial carcinoma and verification in vitro.
    Li Y; Xu K; Zhang Y; Mao H; Qiu Q; Yan Z; Liu X; Du Y; Chen Z
    BMC Cancer; 2023 Oct; 23(1):1021. PubMed ID: 37872487
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of a prognostic model to predict BLCA based on anoikis-related gene signature: preliminary findings.
    Zhu S; Zhao Q; Fan Y; Tang C
    BMC Urol; 2023 Dec; 23(1):199. PubMed ID: 38049825
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical Eosinophil-Associated Genes can Serve as a Reliable Predictor of Bladder Urothelial Cancer.
    Xu C; Song L; Peng H; Yang Y; Liu Y; Pei D; Guo J; Liu N; Liu J; Li X; Li C; Kang Z
    Front Mol Biosci; 2022; 9():963455. PubMed ID: 35936781
    [No Abstract]   [Full Text] [Related]  

  • 28. Cancer-associated fibroblast-derived gene signature discriminates distinct prognoses by integrated single-cell and bulk RNA-seq analyses in breast cancer.
    Fang Z; Han YL; Gao ZJ; Yao F
    Aging (Albany NY); 2024 May; 16(9):8279-8305. PubMed ID: 38728370
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The G protein-coupled receptor-related gene signatures for predicting prognosis and immunotherapy response in bladder urothelial carcinoma.
    Wan Z; Wang Y; Li C; Zheng D
    Open Life Sci; 2023; 18(1):20220682. PubMed ID: 37588995
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Generalized machine learning based on multi-omics data to profile the effect of ferroptosis pathway on prognosis and immunotherapy response in patients with bladder cancer.
    Liu X; Qiu Z; Zhang X; Su Z; Yi R; Zou D; Xie C; Jin N; Long W; Liu X
    Environ Toxicol; 2024 Feb; 39(2):680-694. PubMed ID: 37647346
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Construction and validation of a gene signature related to bladder urothelial carcinoma based on immune gene analysis.
    Xing P; Jiang Z; Liu Y
    BMC Cancer; 2022 Aug; 22(1):926. PubMed ID: 36030212
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comprehensive analysis of scRNA-seq and bulk RNA-seq reveal the characteristics of disulfidptosis and a prognostic signature in BLCA.
    Deng H; Cheng F; Cheng S
    Aging (Albany NY); 2024 Mar; 16(6):5751-5771. PubMed ID: 38507521
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification and verification of eight cancer-associated fibroblasts related genes as a prognostic signature for head and neck squamous cell carcinoma.
    Dong L; Sun Q; Song F; Song X; Lu C; Li Y; Song X
    Heliyon; 2023 Mar; 9(3):e14003. PubMed ID: 36938461
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification and Validation of an Individualized Prognostic Signature of Bladder Cancer Based on Seven Immune Related Genes.
    Qiu H; Hu X; He C; Yu B; Li Y; Li J
    Front Genet; 2020; 11():12. PubMed ID: 32117435
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Integrative analysis of cancer-associated fibroblast signature in gastric cancer.
    Zhao Z; Mak TK; Shi Y; Li K; Huo M; Zhang C
    Heliyon; 2023 Sep; 9(9):e19217. PubMed ID: 37809716
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comprehensive Exploration of Tumor Microenvironment Modulation Based on the ESTIMATE Algorithm in Bladder Urothelial Carcinoma Microenvironment.
    Chen J; Lv B; Zhan Y; Zhu K; Zhang R; Chen B; Jin Y; Li Y; Zheng J; Lin C
    Front Oncol; 2022; 12():724261. PubMed ID: 35237505
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An effective N6-methyladenosine-related long non-coding RNA prognostic signature for predicting the prognosis of patients with bladder cancer.
    Ma T; Wang X; Meng L; Liu X; Wang J; Zhang W; Tian Z; Zhang Y
    BMC Cancer; 2021 Nov; 21(1):1256. PubMed ID: 34802433
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of prognostic cancer-associated fibroblast markers in luminal breast cancer using weighted gene co-expression network analysis.
    Xu A; Xu XN; Luo Z; Huang X; Gong RQ; Fu DY
    Front Oncol; 2023; 13():1191660. PubMed ID: 37207166
    [TBL] [Abstract][Full Text] [Related]  

  • 39. TFRC, associated with hypoxia and immune, is a prognostic factor and potential therapeutic target for bladder cancer.
    Tang R; Wang H; Liu J; Song L; Hou H; Liu M; Wang J; Wang J
    Eur J Med Res; 2024 Feb; 29(1):112. PubMed ID: 38336764
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cancer-associated Fibroblasts in Bladder Cancer: Origin, Biology, and Therapeutic Opportunities.
    Caramelo B; Zagorac S; Corral S; Marqués M; Real FX
    Eur Urol Oncol; 2023 Aug; 6(4):366-375. PubMed ID: 36890105
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.